Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DarioHealth (DRIO) Cash & Equivalents (2016 - 2025)

DarioHealth filings provide 14 years of Cash & Equivalents readings, the most recent being $21.8 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 21.47% to $21.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.8 million, a 21.47% decrease, with the full-year FY2025 number at $21.8 million, down 21.47% from a year prior.
  • Cash & Equivalents hit $21.8 million in Q4 2025 for DarioHealth, down from $31.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $81.2 million in Q1 2021 to a low of $15.5 million in Q3 2024.
  • Median Cash & Equivalents over the past 5 years was $37.8 million (2023), compared with a mean of $41.9 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 412.9% in 2021 and later plummeted 64.57% in 2024.
  • DarioHealth's Cash & Equivalents stood at $35.9 million in 2021, then soared by 37.3% to $49.4 million in 2022, then dropped by 25.45% to $36.8 million in 2023, then decreased by 24.55% to $27.8 million in 2024, then decreased by 21.47% to $21.8 million in 2025.
  • The last three reported values for Cash & Equivalents were $21.8 million (Q4 2025), $31.9 million (Q3 2025), and $22.0 million (Q2 2025) per Business Quant data.